- Astellas, Pfizer look to expand Xtandi’s patient base after 8 years with new prostate cancer win.FiercePharma
- Enzalutamide/Leuprolide prolongs MFS in nmHSPC with high-risk biochemical recurrenceTargeted oncology
- Pfizer, Astellas’ Xtandi meets primary endpoint in Phase 3 trial in prostate cancer subtypeSeeking Alpha
- Enzalutamide plus leuprolide improves MFS in nonmetastatic castration-sensitive prostate cancer.OncLive
- Enzalutamide plus ADT improves time to PSA progression in mHSPCTargeted oncology
- See full coverage on Google News
[ad_2]
Comments